|

Allergy Delabeling in Antibiotic Stewardship - Intervention

RECRUITINGN/ASponsored by Ebbing Lautenbach
Actively Recruiting
PhaseN/A
SponsorEbbing Lautenbach
Started2026-04-20
Est. completion2028-11
Eligibility
Age18 Years+
Healthy vol.Accepted
Locations1 site
View on ClinicalTrials.gov →

NCT07133074

Summary

The overall goal of the RENEW-IN intervention is to assess the impact of a BL allergy delabeling intervention on antibiotic use and clinical outcomes in patients with a hematologic malignancy.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* all patients with a hematologic malignancy (including Hodgkin and non-Hodgkin lymphoma, leukemia, and myeloma) admitted to an inpatient oncology service
* reported history of a beta-lactam (BL) allergy (i.e., penicillin, cephalosporin, and/or carbapenem)

Exclusion Criteria:

* patients with a history of severe cutaneous adverse reaction
* patients with a history of Stevens-Johnson syndrome
* patients with a history of toxic epidermal necrolysis
* patients with a history of drug-induced exfoliative dermatitis
* patients with a history of drug reaction with eosinophilia and systemic symptoms
* patients with a history of acute generalized exanthematous pustulosis

Conditions3

Beta Lactam AllergyCancerHematologic Malignancy

Locations1 site

Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, 19104
Ebbing Lautenbach, MD, MPH, MSCE

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.